Core Viewpoint - The company is actively researching and developing products related to the application of iodides in the perovskite field, with ongoing projects but no products available for sale yet [1]. Group 1 - The company has acknowledged the potential of iodides in the perovskite sector [1]. - Technical research and product development efforts are currently underway [1]. - The related R&D projects are in progress but have not yet resulted in product sales [1].

Group 1 - The company is exploring the application of iodides in the perovskite field and has initiated technical research and product development in this area [2] - Current research and development projects related to iodides and perovskites are in progress, but no products have been commercialized yet [2]

Group 1 - The core business of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. includes the research, production, and sales of fine chemicals, with a focus on organic iodides (74.56% of revenue), specialty functional chemicals (12.79%), trading (9.94%), and others (2.72%) [2] - As of December 10, 2025, the company reported a revenue of 1.073 billion yuan, representing a year-on-year growth of 6.60%, while the net profit attributable to shareholders decreased by 22.53% to 132 million yuan [2] - The company has distributed a total of 88.408 million yuan in dividends since its A-share listing [3] Group 2 - On December 19, 2025, Boyuan shares increased by 0.53%, with a trading volume of 93.8648 million yuan, and a net financing purchase of 448,700 yuan [1] - The total margin trading balance for Boyuan shares reached 142 million yuan, accounting for 3.68% of the circulating market value, which is above the 70th percentile of the past year [1] - As of December 19, 2025, there were no shares sold or repaid in the securities lending market, indicating a high level of demand for borrowing [1]

Group 1 - The core viewpoint of the news is that Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has shown fluctuations in its stock performance and financing activities, indicating potential investor interest and market dynamics [1][2]. Group 2 - On December 18, Boyuan shares fell by 2.24%, with a trading volume of 66.31 million yuan. The financing buy-in amount was 5.13 million yuan, while the financing repayment was 3.34 million yuan, resulting in a net financing buy-in of 1.79 million yuan. The total financing and securities balance reached 142 million yuan [1]. - As of December 18, the financing balance of Boyuan shares was 142 million yuan, accounting for 3.69% of the circulating market value [1]. - In terms of securities lending, there were no shares repaid or sold on December 18, with a remaining balance of 0 shares and 0 yuan [1]. Group 3 - Boyuan, established on August 6, 2008, is located in Shouguang City, Shandong Province, and specializes in the research, production, and sales of fine chemicals, including organic and inorganic iodides, precious metal catalysts, and luminescent materials. The main business revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2]. - For the period from January to September 2025, Boyuan achieved an operating income of 1.073 billion yuan, representing a year-on-year growth of 6.60%. However, the net profit attributable to the parent company was 132 million yuan, a decrease of 22.53% year-on-year [2]. Group 4 - Since its A-share listing, Boyuan has distributed a total of 88.41 million yuan in dividends [3]. - As of September 30, 2025, the top ten circulating shareholders of Boyuan include several new institutional investors, with notable holdings from Zhonghang New Start Flexible Allocation Mixed A (holding 1.3456 million shares) and Hong Kong Central Clearing Limited (holding 964,400 shares) [3].

Group 1 - The core point of the article is that Boyuan Co., Ltd. (301617) has officially entered the trial production phase of its 4000 tons/year inorganic iodide production project on December 5, 2025 [1]

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：董秘你好，其4000吨无机碘化物项目（含碘化锂）预 计在2025年底建设完毕并试生产，请问现在是否已如期进入试生产阶段？ 博苑股份（301617.SZ）12月18日在投资者互动平台表示，尊敬的投资者，您好！公司4000吨/年无机碘 化物生产项目，已于2025年12月5日正式进入试生产阶段。感谢您的关注和支持！ ...

Group 1 - The core technology developed by the company allows for the recovery of useful elements such as iodine, bromine, platinum, palladium, rhodium, and ruthenium from waste materials in various industries, achieving the same quality as imported raw materials [1] - The company has established a circular economy model by purchasing waste materials generated during production from clients or other enterprises and extracting key raw materials through recycling [1] - This technology significantly reduces dependence on external raw materials and production costs, effectively mitigating risks associated with fluctuations in imported raw material prices, while providing economic and environmental benefits [1] Group 2 - The company has accumulated 17 years of technical expertise, evolving from a startup in a barren area to a leading enterprise in the iodide industry listed on the Shenzhen Stock Exchange [2] - The company has established itself in various segments, including organic iodides, inorganic iodides, and luminescent materials, and has participated in the formulation of 3 industry standards and 11 group standards [2] Group 3 - The core management team has remained stable over the years, with a commitment to not suppress employee wages and maintaining a robust compensation management system [3] - The company has implemented stock incentive plans since 2018, allowing core executives and young technical talents to hold shares, reflecting a shared growth philosophy [3] Group 4 - The company is gaining attention in the solid-state battery sector, where lithium iodide is recognized for its significant importance in solid-state batteries [4] - A strategic cooperation framework agreement was signed with a leading lithium battery company to jointly develop new solid-state electrolyte products with high ionic conductivity and interface stability [4] - Future development plans include extending product offerings into high-value downstream intermediates and expanding into new energy and materials sectors, while also focusing on international market expansion [4]

证券日报网讯12月15日，博苑股份（301617）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东总户数为9113户。 ...

（编辑 王雪儿） 证券日报网讯 12月15日，博苑股份在互动平台回答投资者提问时表示，目前，公司碘原料来源采用"资 源综合利用回收+进口补充"的双渠道模式。若未来对碘资源的需求进一步增长，公司将根据实际情况 动态调整采购策略与来源比例，以确保供应稳定。 ...

Group 1 - The company has developed recycling technology that extracts useful elements such as iodine, bromine, platinum, palladium, rhodium, and ruthenium from waste in various industries, achieving zero iodine discharge in treated wastewater [1] - The recycling technology significantly reduces dependence on imported raw materials and production costs, effectively addressing the risks associated with price fluctuations of imported materials while providing economic and environmental benefits [1] - The company has a stable core management team and has established a comprehensive salary management system, ensuring steady salary growth for employees alongside business expansion [2] Group 2 - The company is gaining attention in the solid-state battery sector, particularly due to the importance of lithium iodide in solid-state batteries, and has signed a strategic cooperation agreement with a leading lithium battery company to develop new solid-state electrolyte products [3] - The company aims to extend its product offerings into high-value downstream intermediates and expand into new energy and materials sectors, enhancing its product matrix and customer structure [3] - The company plans to strengthen collaborations with industry leaders and gradually expand into overseas markets to enhance its international competitiveness [3]